Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Judge Recused From Glivec Patent Case In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India

You may also be interested in...



Novartis Says Adverse Gleevec Ruling Would Impact Outlook For India

As India’s Supreme Court prepares to deliver a landmark verdict next week on the patentability of Gleevec, Novartis prepares for stormy weather.

Is India Falling Behind Its Neighbors In Attracting Clinical Research?

During the USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.

Is India Falling Behind Its Neighbors In Attracting Clinical Research?

During the annual USA-India Chamber of Commerce biopharma summit, participants discussed the pros and cons of doing research in India, and pointed to key policy issues that must be resolved to spur more clinical trials.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC079222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel